Figure 2
Figure 2. Kaplan-Meier estimate of survival in the study patients’ population stratified by treatment group (BAT vs ruxolitinib) and molecular score (HMR vs LMR).

Kaplan-Meier estimate of survival in the study patients’ population stratified by treatment group (BAT vs ruxolitinib) and molecular score (HMR vs LMR).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal